Status: Recruiting
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.
Participants needed: 12
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: TherornaUpdated: Nov 24, 2025Locations: 1
Eligibility criteria
The patient provides written informed consent for the study. [+13]
History of any therapeutic HPV vaccination. History of any live viral vaccine or... [+19]